As concerns persist over the safety of medicines made overseas, the U.S. FDA recently took the opportunity to tout data showing the number of facilities inspected in foreign countries had increased 20% over the most recent five-year period. Specifically, the agency inspected 993 foreign plants in fiscal year 2014 compared with 1,245 in fiscal year 2018. At the same time, though, the data indicates that the U.S. regulatory agency inspected fewer domestic facilities during that same period – 1,869 versus 1,662, which amounts to a 12.5% drop. Learn More